文献速递艾滋病与性传播感染

美国高危顺性别女性暴露前预防示范项目结果

Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
PubMed 文献 · Clin Infect Dis · 2021-01-01

本研究为48周单臂开放标签示范项目,纳入136名有HIV感染风险的顺性别女性,每日口服TDF/FTC,并通过双向短信和基于干血斑替诺福韦二磷酸浓度的依从性咨询进行支持。48周时62%保留在研究中,46%仍使用PrEP;56%的参与者至少有一次药物浓度符合每周6剂,仅18%在所有访视中均达到该水平;无HIV新发感染,发生4例细菌性性传播感染。结论认为多数参与者未达到有效保护性药物浓度所需的依从性。

要点

  • 48周时仅46%的参与者仍在使用PrEP,保留率为62%。
  • 56%的参与者至少一次药物浓度符合每周6剂,仅18%持续达标。
  • 研究期间无HIV新发感染,发生4例细菌性性传播感染。

核心结论

  • 多数研究参与者未达到有效保护性药物浓度所需的PrEP依从性。
  • 需要进一步研究顺性别女性不依从和低保留率的原因。

研究设计与样本

  • 48周单臂开放标签示范研究,纳入136名≥18岁有HIV感染风险的顺性别女性。
  • 每日口服TDF/FTC,采用双向短信和基于干血斑替诺福韦二磷酸浓度的依从性咨询支持。
  • 研究访视在基线、第4周、第12周,之后每季度一次直至第48周。

主要发现

  • enrolling 136 women (mean age 40 years, SD 11; 38% non-Hispanic Black, 19% Latina).
  • At 48 weeks, 84 (62%) participants were retained and 62 (46%) remained on PrEP.
  • More than one-third (12/31) of those on study but off PrEP discontinued TDF/FTC due to side effects; 1 adverse event led to study discontinuation.
  • Of 120 participants with drug concentrations measured, 67 (56%) had at least 1 concentration consistent with 6 doses/week; 22 (18%) had consistent ≥6 doses/week across all study visits attended.
  • There were no incident HIV infections and 4 incident bacterial sexually transmitted infections.

关键数值与推荐

  • 48周保留率62%(84/136),PrEP持续使用率46%(62/136)。
  • 药物浓度符合每周6剂:至少一次者56%(67/120),所有访视持续达标者18%(22/120)。
  • 因副作用停用TDF/FTC者占研究期间未使用PrEP者的三分之一以上(12/31)。

临床怎么用

  • 应加强顺性别女性PrEP依从性支持和保留策略。
  • 可利用药物浓度反馈和短信干预辅助依从性管理。

局限性

  • 单臂开放标签设计,无对照组。
  • 样本量有限,可能影响结果外推。
  • 药物浓度数据仅来自120名参与者,部分访视缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is effective for reducing human immunodeficiency virus (HIV) acquisition among cisgender women. We report results from the first US observational open-label demonstration project of pre-exposure prophylaxis (PrEP) among at-risk cisgender women. METHODS: Adherence Enhancement Guided by Individualized Texting and Drug Levels was a 48-week, single-arm, open-label demonstration study of daily oral TDF/FTC in cisgender women ≥18 years old at risk for HIV. Adherence was supported using 2-way text messaging and titrated adherence counseling based on rapid-turnaround tenofovir diphosphate concentrations from dried blood spots. Study visits occurred at baseline, weeks 4 and 12, and quarterly through week 48. Outcomes included TDF/FTC adherence, retention, and persistence. RESULTS: From June 2016 to October 2018, 136 cisgender women enrolled (mean age, 40 years (standard deviation, 11); 38% non-Hispanic Black and 19% Latina). At 48 weeks, 84 (62%) participants were retained and 62 (46%) remained on PrEP. More than one-third (12/31) of those on study but off PrEP throughout the study discontinued TDF/FTC because of side effects, and 1 adverse event led to study discontinuation. Of 120 participants with drug concentrations measured, 67 (56%) had at least 1 concentration consistent with 6 doses/week; 22 (18%) had consistent ≥6 doses/week across all study visits attended. There were no incident HIV infections and 4 incident bacterial sexually transmitted infections. CONCLUSION: Adequate PrEP adherence for protective drug concentrations was not achieved for most study participants. More work needs to be done to fully explicate the reasons for nonadherence and low retention in cisgender women.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Blumenthal J, Jain S, He F, et al. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. Clin Infect Dis. 2021. PMID: 33864370. doi:10.1093/cid/ciab328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。